Aarvik
Aarvik Therapeutics Announces Investment by Laurus Labs in Aarvik Series Seed 2 Round
Aarvik Therapeutics Announces Successful Series Seed 2 Financing Round
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
Aarvik Therapeutics Announces Validation of Novel Tetravalent Antibody Platform
Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform
Aarvik Therapeutics Appoints Dr. Richard Scheller to Board of Directors, Dr. Melissa Starovasnik to Scientific Advisory Board, and Announces Scientific Team
Aarvik Therapeutics (formerly Aarkus Therapeutics) Announces Successful Series Seed Financing
Aarvik Therapeutics Launches with a Novel Modular Antibody Technology Platform
By James Waldron FierceBiotech
